





## LABORATORY REPORT

Cov/Ara - Mala - 20 Vacra - Cosa ID - 20000

Name : Mr. KUMAR SONI Sex/Age : Male / 39 Years Case ID : 30908001149

Ref. By : MEDIWHEEL FULL BODY HEALTH Dis. At : Pt. ID : CHECKUP MALE BELOW 40

Bill. Loc. : SPH OPD Pt. Loc :

Report Date and Time : 23-Sep-2023 11:08 Acc. Remarks : Ref Id2 :

TEST	RESUI	LTS UNIT	т в	IOLOGICAL RE	F. INTERVAL	REMARKS
		HAEMO	OGRAM REP	ORT		
HB AND INDICES						
Haemoglobin	15.3	G%	. 1	3.00 - 17.00		
RBC (Electrical Impedance)	4.83	milli	ions/cumm 4	.50 - 5.50		
PCV(Calc)	48.06	%	4	0.00 - 50.00		
MCV (RBC histogram)	99.5	fL	8	33.00 - 101.00		
MCH (Calc)	31.7	pg	2	7.00 - 32.00		
MCHC (Calc)	31.8	gm/	dL 3	1.50 - 34.50		
RDW (RBC histogram)	11.90	%	1	1.00 - 16.00		
TOTAL AND DIFFERENTIAL WI	BC COUNT					
Total WBC Count	L 3970	/µL	4	000.00 - 10000	.00	
Neutrophil	[%] 62	%	<b>EXPECTED VAI</b> 40.00 - 70.0		[Abs] 2461	EXPECTED VALUES /µL 2000.00 - 7000.00
Lymphocyte	29	%	20.00 - 40.0	0	1151	μL 1000.00 - 3000.00
Eosinophil	03	%	1.00 - 6.00		119	μL 20.00 - 500.00
Monocytes	06	%	2.00 - 10.00		238	μL 200.00 - 1000.00
Basophil	0.0	%	0.00 - 2.00		0	μL 0.00 - 100.00
PLATELET COUNT						
Platelet Count	15500	)0 /μL	1	50000.00 - 410	00.00	
MPV	11.90	fL	6	5.5 - 12		
PDW	H <b>16.5</b>		9	9 - 16		

Method:

TLC-SF cube technology(Flow Cytometry+ fluorescence),

DC by microscopy,

Platelet count by electrical impedance+/-SF cube technology

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Dir Dijai Gilaii

Consultant Pathologist GMC No. G-11309 **Page 1 of 9** 



Name





### LABORATORY REPORT

Sex/Age : Male / 39 Years Case ID: 30908001149

: Mr. KUMAR SONI Ref. By : MEDIWHEEL FULL BODY HEALTH Pt. ID Dis. At

**CHECKUP MALE BELOW 40** 

Bill. Loc. : SPH OPD Pt. Loc

Reg Date and Time : 23-Sep-2023 09:24 Sample Type : Whole Blood EDTA Mobile No. : Sample Date and Time : 23-Sep-2023 09:24 Ref Id1 Sample Coll. By : non : 23-Sep-2023 16:06 Acc. Remarks Ref Id2 Report Date and Time

**TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS** 

### HAEMATOLOGY INVESTIGATIONS

**ESR**Westergren Method mm after 1hr 3 - 15

**BLOOD GROUP AND RH TYPING (Erythrocyte Magnetized Technology)** (Both Forward and Reverse Group)

**ABO Type** 

Rh Type **POSITIVE** 

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah Printed On: 05-Dec-2023 11:17

Consultant Pathologist GMC No. G-11309 Page 2 of 9







### LABORATORY REPORT

RATORT RELORT

Name : Mr. KUMAR SONI Sex/Age : Male / 39 Years Case ID : 30908001149

Ref. By : MEDIWHEEL FULL BODY HEALTH Dis. At : Pt. ID : CHECKUP MALE BELOW 40

Bill. Loc. : SPH OPD Pt. Loc :

Reg Date and Time : 23-Sep-2023 09:24 Sample Type : Plasma Fluoride F,Plasma | Mobile No. :

Fluoride PP,Whole Blood

EDTA

Sample Date and Time : 23-Sep-2023 09:24 Sample Coll. By : non Ref Id1

Report Date and Time : 23-Sep-2023 13:02 Acc. Remarks : Ref Id2

TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

**Plasma Glucose - F** H **102.59** mg/dL 70 - 100 FUS: NIL

**Plasma Glucose - PP 108.81** mg/dL 70 - 140 PPUS: NIL

**Glycated Haemoglobin Estimation** 

**HbA1C** 5.3 % of total Hb <5.7: Normal

Immunoturbidimetric 5.7-6.4: Prediabetes

>=6.5: Diabetes

Estimated Avg Glucose (3 Mths) 105.41 mg/dL Not available Calculated

Please Note change in reference range as per ADA 2021 guidelines.

Interpretation :

HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycemic control.

Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia.

 $\label{localization} \textbf{Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients.}$ 

Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA.

In such circumstances glycemic control can be monitored using plasma glucose levels or serum Fructosamine.

The A1c target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Deven Desai

Consultant Pathologist GMC No. G-12429

Page 3 of 9



Name





### LABORATORY REPORT

Sex/Age : **Male** / **39 Years** Case ID : **30908001149** 

Ref. By ; MEDIWHEEL FULL BODY HEALTH Dis. At : Pt. ID :

CHECKUP MALE BELOW 40

Bill. Loc. : SPH OPD Pt. Loc

Reg Date and Time : 23-Sep-2023 09:24 Sample Type : Serum Mobile No. :

Sample Date and Time : 23-Sep-2023 09:24 Sample Coll. By : non Ref Id1 :

Report Date and Time : 23-Sep-2023 11:05 Acc. Remarks : Ref Id2 :

TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

## **BIOCHEMICAL INVESTIGATIONS**

## **Lipid Profile**

Cholesterol Colorimetric, CHOD-POD	H <b>215.07</b>	mg/dL	110 - 200	
HDL Cholesterol	53.2	mg/dL	40 - 60	
Triglyceride GPO-POD	130.57	mg/dL	40 - 200	
VLDL Calculated	26.11	mg/dL	10 - 40	
Chol/HDL Calculated	4.04		0 - 4.1	
LDL Cholesterol Calculated	H <b>135.76</b>	mg/dL	0.00 - 100.00	

### NEW ATP III GUIDELINES (MAY 2001), MODIFICATION OF NCEP

LDL CHOLESTEROL	CHOLESTEROL	HDL CHOLESTEROL	TRIGLYCERIDES
Optimal<100	Desirable<200	Low<40	Normal<150
Near Optimal 100-129	Border Line 200-239	High >60	Border High 150-199
Borderline 130-159	High >240		High 200-499
High 160-189			

- LDL Cholesterol level is primary goal for treatment and varies with risk category and assessment
- For LDL Cholesterol level Please consider direct LDL value
  - Risk assessment from HDL and Triglyceride has been revised. Also LDL goals have changed.
- Detail test interpreation available from the lab
- All tests are done according to NCEP guidelines and with FDA approved kits.
- · LDL Cholesterol level is primary goal for treatment and varies with risk category and assesment

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dir Dila

Dr. Bijal Shah

Consultant Pathologist GMC No. G-11309 **Page 4 of 9** 



Name





## LABORATORY REPORT

Ref. By ; MEDIWHEEL FULL BODY HEALTH Dis. At : Pt. ID :

CHECKUP MALE BELOW 40

Bill. Loc. : SPH OPD Pt. Loc

Reg Date and Time: 23-Sep-2023 09:24Sample Type: SerumMobile No.Sample Date and Time: 23-Sep-2023 09:24Sample Coll. By: nonRef Id1:Report Date and Time: 23-Sep-2023 12:28Acc. Remarks:Ref Id2:

TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

## **BIOCHEMICAL INVESTIGATIONS**

### **Liver Function Test**

			LIVEI I UIICUOII I	<u> </u>	
S.G.P.T.		25.35	U/L	0 - 63	
S.G.O.T.		23.83	U/L		
Alkaline Phosphatase Modified IFCC method		92.21	U/L	40 - 150	
Proteins (Total) Colorimetric, Biuret	L	5.96	gm/dL	6.40 - 8.30	
<b>Albumin</b> Bromo Cresol Green		4.74	g/dL	3.4 - 5.0	
Globulin Calculated	L	1.22	gm/dL	2 - 4.1	
A/G Ratio Calculated	Н	3.9		1.0 - 2.1	
Bilirubin Total Photometry		1.16	mg/dL	0.3 - 1.2	
Bilirubin Conjugated Diazotization reaction		0.32	mg/dL	0 - 0.50	
Bilirubin Unconjugated Calculated	Н	0.84	mg/dL	0 - 0.8	

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

O David

Dr. Deven Desai

Consultant Pathologist GMC No. G-12429

Page 5 of 9



Name





## LABORATORY REPORT

Ref. By ; MEDIWHEEL FULL BODY HEALTH Dis. At : Pt. ID :

CHECKUP MALE BELOW 40

Bill. Loc. : SPH OPD Pt. Loc

Reg Date and Time : 23-Sep-2023 09:24 Sample Type : Serum | Mobile No. : Sample Date and Time : 23-Sep-2023 09:24 Sample Coll. By : non | Ref Id1 :

Report Date and Time : 23-Sep-2023 12:27 Acc. Remarks : Ref Id2

TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

## **BIOCHEMICAL INVESTIGATIONS**

## **Renal Function Test**

Tonal Function Foot							
Urea Urease/GLDH		20.34	mg/dL	19.01 - 44.1			
Creatinine Jaffe compensated		1.16	mg/dL	0.70 - 1.30			
Uric Acid Uricase-Peroxidase method		6.40	mg/dL	3.5 - 7.2			
Sodium ISE		143.0	mmol/L	136 - 145			
Potassium ISE		4.27	mmol/L	3.5 - 5.1			
Chloride ISE		103.5	mmol/L	98 - 107			
Calcium Arsenazo III	Н	10.46	mg/dL	8.4 - 10.2			

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Deven Desai

Consultant Pathologist GMC No. G-12429

Page 6 of 9



Name





### LABORATORY REPORT

Ref. By : MEDIWHEEL FULL BODY HEALTH Dis. At : Pt. ID :

CHECKUP MALE BELOW 40

Bill. Loc. : SPH OPD Pt. Loc

Reg Date and Time : 23-Sep-2023 09:24 Sample Type : Serum Mobile No. : Sample Date and Time : 23-Sep-2023 09:24 Sample Coll. By : non Ref Id1 :

Report Date and Time : 23-Sep-2023 09.24 Sample Coll. by : non Refind : Ref

TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

## **BIOCHEMICAL INVESTIGATIONS**

# Thyroid Function Test

Triiodothyronine (T3)	1.04	ng/mL	0.70 - 2.04
Thyroxine (T4) CMIA	10.5	μg/dL	4.6 - 10.5
TSH CMIA	H <b>4.23</b>	μIU/mL	0.4 - 4.2

#### **INTERPRETATIONS**

Useful for Monitoring patients on thyroid replacement therapy, Confirmation of thyroid-stimulating hormone (TSH) suppression in thyroid cancer patients on thyroxine therapy, for Prediction of thyrotropin-releasing hormone-stimulated TSH response, as An aid in the diagnosis of primary hyperthyroidism, for Differential diagnosis of hypothyroidism.

The ability to quantitate circulating levels of thyroid-stimulating hormone (TSH) is important in evaluating thyroid function. It is especially useful in the differential diagnosis of primary (thyroid) from secondary (pituitary) and tertiary (hypothalamus) hypothyroidism. In primary hypothyroidism, TSH levels are significantly elevated, while in secondary and tertiary hypothyroidism, TSH levels are low or normal. Concentrations of 5.1 mIU/ml to 7.0 mIU/ml are considered borderline hypothyroid

#### **CAUTIONS**

Sick, hospitalized patients may have falsely low or transiently elevated thyroid stimulating hormone.

Some patients who have been exposed to animal antigens, either in the environment or as part of treatment or imaging procedure, may have circulating antianimal antibodies present. These antibodies may interfere with the assay reagents to produce unreliable results.

TSH ref range in Pregnacy Reference range (microlU/ml)

First trimester 0.24 - 2.00 Second trimester 0.43-2.2 Third trimester 0.8-2.5

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Bijal Shah

Consultant Pathologist GMC No. G-11309 Page 7 of 9







### LABORATORY REPORT

Ref. By : MEDIWHEEL FULL BODY HEALTH Dis. At : Pt. ID :

CHECKUP MALE BELOW 40

Bill. Loc. : SPH OPD Pt. Loc

Reg Date and Time : 23-Sep-2023 09:24 Sample Type : Spot Urine Mobile No. : Sample Date and Time : 23-Sep-2023 09:24 Sample Coll. By : non Ref Id1 :

Report Date and Time : 23-Sep-2023 14:21 Acc. Remarks : Ref Id2 :

TEST RESULTS UNIT BIOLOGICAL REF RANGE REMARKS

### **URINE EXAMINATION (STRIP METHOD AND FLOWCYTOMETRY)**

Physical examination

Name

Colour Pale yellow

Transparency Clear

Chemical Examination By Sysmex UC-3500

**Sp.Gravity** 1.015 1.003 - 1.035

рΗ 7.0 4.6 - 8 Leucocytes (ESTERASE) **Negative** Negative **Protein** Negative Negative Glucose **Negative** Negative **Ketone Bodies Urine** Negative Negative Urobilinogen **Normal** Negative Negative **Bilirubin** Negative **Blood** Negative Negative **Nitrite** Negative Negative

Flowcytometric Examination By Sysmex UF-5000

 Leucocyte
 Nil
 /HPF
 Nil

 Red Blood Cell
 Nil
 /HPF
 Nil

Epithelial CellNil/HPFPresent(+)BacteriaNil/ulNil

 Yeast
 Nil
 /ul
 Nil

 Cast
 Nil
 /LPF
 Nil

 Crystals
 Nil
 /HPF
 Nil

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

Dr. Rijal Sha

Dr. Bijal Shah

Printed On: 05-Dec-2023 11:17

Consultant Pathologist GMC No. G-11309

Page 8 of 9







## LABORATORY REPORT

Name : Mr. KUMAR SONI Sex/Age : Male / 39 Years Case ID : 30908001149

Ref. By : MEDIWHEEL FULL BODY HEALTH Dis. At : Pt. ID : CHECKUP MALE BELOW 40

Bill. Loc. : SPH OPD Pt. Loc

Reg Date and Time : 23-Sep-2023 09:24 Sample Type : Spot Urine Mobile No. : Sample Date and Time : 23-Sep-2023 09:24 Sample Coll. By : non Ref Id1 :

Report Date and Time : 23-Sep-2023 14:21 Acc. Remarks : Ref Id2 :

Parameter	Unit	Expected value		Resu	lt/Notation	15	
			Trace	+	++	+++	++++
pH	-	4.6-8.0	1 11 1 11 11 33	- 2			20 11
SG	-	1.003-1.035	100				2/
Protein	mg/dL	Negative (<10)	10	25	75	150	500
Glucose	mg/dL	Negative (<30)	30	50	100	300	1000
Bilirubin	mg/dL	Negative (0.2)	0.2	1	3	6	-0
Ketone	mg/dL	Negative (<5)	5	15	50	150	1 2
Urobilinogen	mg/dL	Negative (<1)	1	4	8	12	51
Parameter	Unit	Expected value	Result/Notifications			50 751	
			Trace	+	++	+++	++++
Leukocytes (Strip)	/micro L	Negative (<10)	10	25	100	500	-
Nitrite(Strip)	-	Negative	-	-	-	_	-2)
Erythrocytes(Strip)	/micro L	Negative (<5)	10	25	50	150	250
Pus cells (Microscopic)	/hpf	<5	ā	5	97-9	7.	70
Red blood	/hnf	-2	550	2.5	5,500		500

<2

<2

 Fnd Of	Report	
 LIIU OI	1/CDOIL	

Note:(LL-VeryLow,L-Low,H-High,HH-VeryHigh ,A-Abnormal)

/hpf

/lpf

Dr. D::

Dr. Bijal Shah

Consultant Pathologist GMC No. G-11309 Page 9 of 9

cells(Microscopic)

Cast (Microscopic)

<sup>#</sup> For test performed on specimens received or collected from non-NSRL locations, it is presumed that the specimen belongs to the patient named or identified as labeled on the container/test request and such verification has been carried out at the point generation of the said specimen by the sender. NSRL will be responsible Only for the analytical part of test carried out. All other responsibility will be of referring Laboratory.